Associated Papers
Preclinical characterization and first-in-human, phase I trial of the novel ALK inhibitor dirozalkib in advanced non-small cell lung cancer.
Ai X et al.
European Journal of Cancer (oxford, England : 1990), 2026
Presence of On-Target Resistant Mutation in Pre-Treatment Samples of ALK Fusion Gene Positive Lung Cancer Patients.
Li W et al.
Cancers, 2025
ALK F1174S mutation impairs ALK kinase activity in EML4-ALK variant 1 and sensitizes EML4-ALK variant 3 to crizotinib.
Guan J et al.
Frontiers in Oncology, 2023
A computational examination of the therapeutic advantages of fourth-generation ALK inhibitors TPX-0131 and repotrectinib over third-generation lorlatinib for NSCLC with ALK F1174C/L/V mutations.
Balasundaram A et al.
Frontiers in Molecular Biosciences, 2023
Durable clinical response to ALK tyrosine kinase inhibitors in ALK-rearranged non-small cell lung cancer: a case report.
Hu H et al.
Translational Cancer Research, 2022
Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK-positive non-small-cell lung cancer.
Wolf J et al.
Esmo Open, 2022
One-Step Polymerase Chain Reaction-Free Nanowire-Based Plasma Cell-Free DNA Assay to Detect EML4-ALK Fusion and to Monitor Resistance in Lung Cancer.
Lee Y et al.
The Oncologist, 2021
NGS-based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment.
Sánchez-Herrero E et al.
Molecular Oncology, 2021
TPX-0131, a Potent CNS-penetrant, Next-generation Inhibitor of Wild-type ALK and ALK-resistant Mutations.
Murray BW et al.
Molecular Cancer Therapeutics, 2021
Exceptional response to the ALK and ROS1 inhibitor lorlatinib and subsequent mechanism of resistance in relapsed ALK F1174L-mutated neuroblastoma.
Liu T et al.
Cold Spring Harbor Molecular Case Studies, 2021
Treatment of Non-Small-Cell Lung Cancer Based on Circulating Cell-Free DNA and Impact of Variation Allele Frequency.
Bustamante Alvarez JG et al.
Clinical Lung Cancer, 2021
Targeted Therapy of Papillary Thyroid Cancer: A Comprehensive Genomic Analysis.
Hescheler DA et al.
Frontiers in Endocrinology, 2021
Detection of circulating tumor DNA in patients of operative colorectal and gastric cancers.
Suzuki T et al.
Oncotarget, 2020
Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of ALK Mutation Status.
Fukuda K et al.
Cancer Research, 2019
Anaplastic lymphoma kinase inhibition in metastatic non-small cell lung cancer: clinical impact of alectinib.
Muller IB et al.
Oncotargets and Therapy, 2017
The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.
Zhang S et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2016
Different histopathology but the same clonality: ALK rearrangement in a patient with metastatic non-small-cell lung cancer.
Zhao J et al.
International Journal of Clinical and Experimental Pathology, 2015
The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.
Friboulet L et al.
Cancer Discovery, 2014